

January 16, 2023

**Acurx Pharmaceuticals**

# **Acurx Pharmaceuticals to Present at the Emerging Growth Conference on January 25, 2023**

*Acurx invites individual and institutional investors, financial advisors and analysts to attend its real-time, interactive question and answer session at the Emerging Growth Conference*

STATEN ISLAND, N.Y., Jan. 16, 2023 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, is pleased to announce that it has been invited to present at the Emerging Growth Conference on January 25, 2023. This live, interactive online event will provide existing stockholders and the investment community with the opportunity to interact with the Company's President & Chief Executive Officer, David P. Luci, in real time. Mr. Luci will conduct an interview and open the floor for questions. Please submit your questions in advance to [Questions@EmergingGrowth.com](mailto:Questions@EmergingGrowth.com) or ask your questions during the event and Mr. Luci will do his best to respond to as many as possible.

Details of this event are as follows:

Date: Wednesday, January 25, 2023

Time: 9:40 am to 10:10 am Eastern Time

Webcast: [https://goto.webcasts.com/starthere.jsp?ei=1575092&tp\\_key=9111d280ed&sti=acxp](https://goto.webcasts.com/starthere.jsp?ei=1575092&tp_key=9111d280ed&sti=acxp)

This live, interactive online event will provide current stockholders and the investment community the opportunity to interact with David P. Luci. As time permits, Mr. Luci may be able to respond to questions from participants.

If attendees are not able to join the event live on the day of the conference, an archived webcast will also be made available on EmergingGrowth.com and on the Emerging Growth YouTube Channel, <http://www.YouTube.com/EmergingGrowthConference>. We will release a link to that after the event.

## **About the Emerging Growth Conference**

The Emerging Growth conference is an effective way for public companies to present and communicate their new products, services and other major announcements to the investment community from the convenience of their office, in a time efficient manner.

The Conference focus and coverage includes companies in a wide range of growth sectors with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long term growth. Its audience includes potentially tens of thousands of Individual and Institutional investors, as well as Investment advisors and analysts.

All sessions will be conducted through video webcasts and will take place in the Eastern

time zone.

### **About Acurx Pharmaceuticals, Inc.**

Acurx Pharmaceuticals is a clinical stage biopharmaceutical company focused on developing an entirely new class of antibiotics for difficult to treat infections. The Company's approach is to develop antibiotic candidates that target the DNA polymerase III C enzyme and its R&D pipeline includes antibiotic product candidates that target Gram-positive bacteria, including *Clostridioides difficile*, methicillin-resistant *Staphylococcus aureus* (MRSA), vancomycin resistant *Enterococcus* (VRE) and drug-resistant *Streptococcus pneumoniae* (DRSP). To learn more about Acurx Pharmaceuticals and its product pipeline, please visit [www.acurxpharma.com](http://www.acurxpharma.com)

### **Forward-Looking Statements**

Any statements in this press release about our future expectations, plans and prospects, including statements regarding our strategy, future operations, prospects, plans and objectives, and other statements containing the words "believes," "anticipates," "plans," "expects," and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: whether ibezapolstat will benefit from the QIDP designation; whether ibezapolstat will advance through the clinical trial process on a timely basis; whether the results of the clinical trials of ibezapolstat will warrant the submission of applications for marketing approval, and if so, whether ibezapolstat will receive approval from the FDA or equivalent foreign regulatory agencies where approval is sought; whether, if ibezapolstat obtains approval, it will be successfully distributed and marketed; and other risks and uncertainties described in the Company's annual report filed with the Securities and Exchange Commission on Form 10-K for the year ended December 31, 2021, and in the Company's subsequent filings with the Securities and Exchange Commission. Such forward-looking statements speak only as of the date of this press release, and Acurx disclaims any intent or obligation to update these forward-looking statements to reflect events or circumstances after the date of such statements, except as may be required by law.

### **Investor Contact:**

Acurx Pharmaceuticals, Inc.

David P. Luci, President & CEO

Tel: 917-533-1469

Email: [davidluci@acurxpharma.com](mailto:davidluci@acurxpharma.com)

View original content: <https://www.prnewswire.com/news-releases/acurx-pharmaceuticals-to-present-at-the-emerging-growth-conference-on-january-25-2023-301721887.html>

SOURCE Acurx Pharmaceuticals, Inc.